Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Dumont FJ et al. | Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. | 1990 | J. Immunol. | pmid:1688572 |
Woo J et al. | Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. | 1990 | Clin. Exp. Immunol. | pmid:1689226 |
Dumont FJ et al. | The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. | 1990 | J. Immunol. | pmid:1689353 |
Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
Imventarza O et al. | Renal transplantation in baboons under FK 506. | 1990 | Transplant. Proc. | pmid:1689903 |
Monden M et al. | A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. | 1990 | Transplant. Proc. | pmid:1689904 |
Ericzon BG et al. | Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. | 1990 | Transplant. Proc. | pmid:1689905 |
Murase N et al. | Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. | 1990 | Transplant. Proc. | pmid:1689906 |
Hoffman AL et al. | The effect of FK 506 on small intestine allotransplantation in the rat. | 1990 | Transplant. Proc. | pmid:1689907 |
Lee KK et al. | Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. | 1990 | Transplant. Proc. | pmid:1689908 |
Ueda Y et al. | Induction of graft acceptance after dog kidney or liver transplantation. | 1990 | Transplant. Proc. | pmid:1689909 |
Ohara K et al. | Toxicologic evaluation of FK 506. | 1990 | Transplant. Proc. | pmid:1689910 |
Nalesnik MA et al. | The effect of FK 506 and CyA on the Lewis rat renal ischemia model. | 1990 | Transplant. Proc. | pmid:1689911 |
Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
Propper DJ et al. | FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. | 1990 | Transplantation | pmid:1696409 |
Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
Standaert RF et al. | Molecular cloning and overexpression of the human FK506-binding protein FKBP. | 1990 | Nature | pmid:1696686 |
Tropschug M et al. | Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. | 1990 | Nature | pmid:1696687 |
Randall T | New antirejection drugs anticipated. | 1990 | JAMA | pmid:1696999 |
Metcalfe S et al. | FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. | 1990 | Transplant. Proc. | pmid:1697107 |
Morris RE et al. | A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. | 1990 | Transplant. Proc. | pmid:1697111 |
Woo J et al. | Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. | 1990 | Transplant. Proc. | pmid:1697112 |
Woo J et al. | Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. | 1990 | Transplant. Proc. | pmid:1697113 |
Lee KK et al. | Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. | 1990 | Transplant. Proc. | pmid:1702239 |
Takai K et al. | Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. | 1990 | Clin. Exp. Immunol. | pmid:1702372 |
Okubo Y et al. | FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. | 1990 | Clin. Exp. Immunol. | pmid:1702373 |
Arita C et al. | Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. | 1990 | Clin. Exp. Immunol. | pmid:1702374 |
Woo J et al. | Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. | 1990 | Clin. Exp. Immunol. | pmid:1702375 |
Mattila PS et al. | The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. | 1990 | EMBO J. | pmid:1702384 |
Kawashima H et al. | Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. | 1990 | Invest. Ophthalmol. Vis. Sci. | pmid:1702408 |
Wilkinson PC and Watson EA | FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. | 1990 | Immunology | pmid:1702750 |
Metcalfe S and Milner J | Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. | 1990 | Immunol. Lett. | pmid:1702753 |
Takada K et al. | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. | 1990 | J. Chromatogr. | pmid:1703552 |
Collier SJ | Immunosuppressive drugs. | 1989-1990 | Curr. Opin. Immunol. | pmid:2484794 |
McCauley J et al. | Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. | 1989 Dec 23-30 | Lancet | pmid:2481200 |
Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
Takabayashi K et al. | Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. | 1989 | Clin. Immunol. Immunopathol. | pmid:2466594 |
Morris RE et al. | Immunopharmacology of FK-506. | 1989 | Transplant. Proc. | pmid:2468201 |
Yoshimura N et al. | A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. | 1989 | Transplant. Proc. | pmid:2468202 |
Thomson AW et al. | Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. | 1989 | Transplant. Proc. | pmid:2468203 |
Sanghvi A et al. | Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. | 1989 | Transplant. Proc. | pmid:2468204 |
Ochiai T et al. | Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | 1989 | Transplantation | pmid:2474209 |
Siekierka JJ et al. | FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. | 1989 | J. Immunol. | pmid:2474605 |
Thomson AW and Woo J | Immunosuppressive properties of FK-506 and rapamycin. | 1989 | Lancet | pmid:2474733 |
Todo S et al. | Renal transplantation in baboons under FK 506. | 1989 | Surgery | pmid:2474865 |
Kay JE et al. | Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. | 1989 | Immunology | pmid:2475433 |
Moriyama S | [Experimental tracheal reconstruction by allotransplantation]. | 1989 | Nihon Kyobu Geka Gakkai Zasshi | pmid:2475555 |
Freedman RB | Immunosuppression. Convergence of drug action. | 1989 | Nature | pmid:2477712 |
Siekierka JJ et al. | A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. | 1989 | Nature | pmid:2477714 |